Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 32 of 53 · 2520 articles
A high-profile athlete describing recovery from ulcerative colitis and Crohn’s disease highlights that people with IBD can regain strength and return to demanding activities—something patients and families may find...
Anorectal stricture is a disabling Crohn’s complication that often requires surgery; a validated QoL threshold could help identify who should be prioritised for surgical review. This may make shared decision-making and...
This trial is testing whether a rectally delivered probiotic can change the gut microbiome and promote mucosal healing in people with mild-to-moderate ulcerative colitis (and includes some Crohn's patients). If...
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
This meta-analysis suggests people with IBD face higher risks of major cardiovascular events (heart attack, ischemic heart disease, ischemic stroke), which may matter for monitoring and preventive care. Higher risk...
Researchers report links between copper-driven cell death pathways and IBD biology; identifying cuproptosis-related biomarkers or drugs could open new diagnostic or therapeutic avenues for people with Crohn's disease or...
Diet is a modifiable factor many people with IBD try to use to feel better. This review summarizes current evidence that a Mediterranean-style eating pattern may help quality of life and is linked to lower inflammation...
Noninvasive tools that reliably detect postoperative recurrence could reduce the need for frequent invasive endoscopy and help target earlier intervention for people with Crohn's disease after surgery.
This label update affects people with Crohn’s disease or ulcerative colitis because it spells out approved uses, age ranges, and the official dosing schedules and safety warnings for ustekinumab (STELARA). Changes in the...
The study suggests nickel accumulation and iron deficiency may be linked with more severe IBD. If confirmed, blood metal and micronutrient levels could help researchers understand disease mechanisms and guide nutritional...
If you or your clinician are considering dietary therapy like the CDED for Crohn's disease, microbiome features at baseline may influence who achieves sustained remission. Understanding these links could help personalize...
Reactive TDM can help determine why a child with Crohn's disease is losing response to adalimumab and guide whether to escalate dose or switch biologics, which affects short-term management decisions.
Links between IBD genetic risk and specific adult tissue lesion contexts help researchers understand which cell types and tissue programs may mediate inherited susceptibility. That can guide future biomarker and...
This real-world, multicenter study suggests risankizumab can induce clinical and steroid-free remission and mucosal healing in many patients with Crohn disease who previously failed advanced therapies, which may be...
New oral drugs that act mainly in the gut could offer more convenient options and potentially fewer systemic side effects for people with UC or Crohn’s disease. Early clinical signals and a planned Phase 2 trial mean...
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness. Open the original article for the...
Faster, more accurate capsule endoscopy reading could shorten diagnostic delays and reduce missed small‑bowel lesions in Crohn’s disease. For busy clinics, an AI assistant could cut review time and help less‑experienced...
Antibiotics can change the gut microbiome in ways that may raise IBD risk or worsen disease for some people. Knowing which antibiotic classes and approaches may be less harmful could help patients and clinicians reduce...
Risk-prediction tools like CDPATH™ could help people with Crohn’s disease and their doctors identify higher or lower short-term risk of complications and guide treatment conversations. This study tests how the tool...
Digital self-management programs could help people with active IBD build skills to manage symptoms and quality of life between clinic visits. This trial tests whether such a program is feasible, acceptable, and practical...
Early intestinal ultrasound may predict one-year endoscopic remission in Crohn's disease, offering a noninvasive tool to guide treatment decisions and possibly reduce the need for some colonoscopies.
Perianal fistulizing Crohn's disease is a disabling complication; a subcutaneous form of infliximab could lower treatment burden and expand options if its effectiveness and safety in this specific setting are confirmed.
This global survey shows that people with IBD prioritize symptom relief and psychological well-being over treatment features like administration route or speed of onset. That matters for shared decision-making, trial...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
Guidelines recommend treating objective inflammation even when symptoms are mild because untreated disease can cause complications; the article describes escalation to risankizumab due to endoscopic inflammation, high...
If confirmed, antibody signatures detectable years before symptoms could help identify people at higher risk for IBD and improve understanding of how the disease begins — a step toward earlier diagnosis or future...
Oat beta-glucan is a dietary fibre with prebiotic properties; the review suggests potential benefits seen in animal studies but shows human evidence is limited. Patients and clinicians may care because dietary fibres are...
Identifying patients at higher risk of hospitalization earlier could help clinicians target monitoring or treatment changes before clinical deterioration. Standard lab reference ranges may miss meaningful within-person...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from djournal.com.
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from Przeglad gastroenterologiczny.
Methotrexate is commonly used in IBD, often with biologics, but real‑world data on how long patients stay on it, typical dosing, and safety in large contemporary cohorts are limited.
An externally validated, simple prediction score could help identify patients unlikely to need early aggressive treatment and inform shared decision-making about monitoring and therapy.
This is an official prescribing-label update for an adalimumab biosimilar used to treat Crohn’s disease and ulcerative colitis, including pediatric indications and dosing. Changes to indications or pediatric dosing and...
Life satisfaction and social/work impacts are central to daily functioning for people with IBD. Knowing which social factors relate to lower satisfaction can help patients, caregivers, and clinicians spot who may need...
Dietary therapy (CDED + PEN) was associated with longer remission when families adhered well; since adherence varies, support from a dietitian matters for keeping children in remission.
A patient-centered journey map identifies changing symptom, psychological, and social needs at different stages of Crohn's disease. That can help clinicians and care teams target education, mental-health support, and...
Kidney and urinary problems (acute or chronic kidney injury and kidney stones) occurred in a notable minority of IBD patients in this study and were linked to prior IBD surgery, extensive UC, and cardiometabolic...
Subcutaneous infliximab could offer children with IBD a more convenient dosing route with higher, steadier drug levels while maintaining remission. Insurance and labeling barriers affected access in this US cohort.
Strictures raise the risk that food will get stuck and cause a dangerous blockage. Simple changes to texture, portion size, and eating habits can lower that risk and help you keep a varied diet.
The study found disease-specific antibody changes years before IBD diagnosis, suggesting possible early biomarkers and new clues about how Crohn's disease and ulcerative colitis begin.
This Phase 2a trial tested a new investigational drug, tulisokibart, in people with moderately to severely active Crohn’s disease who have not done well on prior therapies — so patients and clinicians watching new...
The study will prospectively evaluate how often dysplasia occurs, how lesions look and behave after endoscopic resection, and what factors predict local or distant recurrence—information that could change surveillance...
If you or someone you care for has β‑thalassemia major, this report shows that inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) can co-occur and may present diagnostic and management challenges.
The study links ER stress and defective autophagy to increased claudin-2 and tight-junction dysfunction—mechanisms relevant to barrier loss in IBD. Targeting this pathway could eventually inform therapies to preserve...
Cure8 could only read part of this source from dignitymemorial.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and...
Detecting Crohn’s recurrence after bowel surgery is important because recurrence can occur without symptoms. A reliable non-invasive test like intestinal ultrasound could reduce the need for repeated colonoscopies and...
For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...
